Mersana Therapeutics has reported encouraging preliminary data from the Phase 1 trial of its lead antibody-drug conjugate, emiltatug ledadotin (Emi-Le), which targets B7-H4 in patients with advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results